Vascular-disrupting agents in oncology

Expert Opinion on Investigational Drugs

Volumn 22, Issue 3, 2013, Pages 317-328

  Mita, Monica M ^a   Sargsyan, Liza ^a   Mita, Alain C ^a   Spear, Matt ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Angiogenesis inhibitors; Cancer; Vascular disrupting agents; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; OMBRABULIN; PACLITAXEL; PLINABULIN; VADIMEZAN; VERUBULIN;

ACUTE CORONARY SYNDROME; ALGORITHM; ANAPLASTIC THYROID CANCER; ARTHRALGIA; BLOOD PRESSURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FLUSHING; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; ONCOLOGY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SARCOMA; SEROTONIN BLOOD LEVEL; SIDE EFFECT; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84873680173     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.759557     Document Type: Review

References (85)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in metastatic renal cellcarcinoma. N Engl J Med 2007;356:115-24
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-50
5. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;10:3124-9
6. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14(11):1131-8
7. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl): abstract 3550
8. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-31
9. Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045-50
10. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
11. Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22
12. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8
13. Pries AR, Reglin B, Secomb TW. Modeling of angioadaptation: insights for vascular development. Int J Dev Biol 2011;55:399-405
14. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990;9:267-82
15. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer 2005;5:423-35
16. Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009;14:612-20
17. Cooney MM, Heckeren W, Bhakta S. Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nat Clin Pract Oncology 2006;3:682-92
18. Sander A, Schiller J, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12
19. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):abstract 3550
20. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-31
21. Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045-50
22. Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. J Cancer Res Clin Oncol 2011;137:1619-27
23. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy. Int J Cancer 2002;99:1-6
24. Siim BG, Lee AE, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
25. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):abstract 3550
26. A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Na?̈ve Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00653939
27. McKeage MJ, Jameson MB. AS1404-201 Study Group Investigators Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA)-retrospective analysis of pooled data. J Thorac Dis 2010;2:199-204
28. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12
29. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-7
30. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
31. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV nonsmall cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, doubleblind, placebo-controlled, ESCAPE (evaluation of sorafenib, carboplatin, and paclitaxel efficacy in NSCLC) trial. Late breaking abstract presented at 1st European Lung Cancer Conference; 2008
32. Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995;36:143-8
33. Corbett TH, Bissery MC, Wozniak A, et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 1986;4:207-20
34. Lara Jr PN, Douillard J-Y, Nakagawa K, et al. Randomized Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71
35. McKeage MJ, Fong P, Jeffery M, et al. 5,6-dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a Phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
36. Gabra H; AS1404-202 Study Group Investigators. Phase II study of vadimezan combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006;24(Suppl):5032
37. Pili R, Rosenthal M. AS1404-203 study group investigators. Addition of vadimezan (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study. J Clin Oncol 2008;26(Suppl):5007
38. McKeage MJ, Jameson MB. Comparison of safety and efficacy between squaomous and non-squamous non-small cell lung cancer patients in a Phase II study of vadimezan (ASA404). J Clin Oncol 2008;26(Suppl 15):441s
39. McKeage MJ, Reck M, Jameson MB, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/vadimezan) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65(2):192-7
40. ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00662597
41. A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00738387
42. Lara P, Douillard J, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2965-71
43. LoRusso PM, Boerner SA. Clinical Development of vascular disrupting agents: what lessions can we learn from ASA404? J Clin Oncol 2011;29:2952-5
44. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumor vascular targeting agents. Int J of Exp Pathol 2002;83:21-38
45. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing. Anticancer Drugs 1993;4:3-17
46. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelis-cadherin signaling. J Clin Invest 2005;115:2992-3006
47. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34
48. Kolomeichuk SN, Terrano DT, Lyle CS, et al. Distinct signaling pathways of microtubule inhibitors-vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J 2008;275:1889-99
49. Yeung S-CJ, She M, Yang H, et al. Combination chemotherapy including combretastatin A4 Phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab 2007;92:2902-9
50. Xu G, Pan J, Martin C, Yeung S-CJ. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. 2001;86(4):1769-77
51. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose Phase I study in patients with advanced cancer. Clin Cancer Res 2004;10(1 Pt 1):96-100
52. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38
53. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21(15):2815-22
54. Bilenker JH, Flaherty KT, Rosen M, et al. Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin. Clin Cancer Res 2005;11:1527-33
55. Dziba JM, Marcinek R, Venkataraman G, et al. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002;12(12):1063-70
56. Sosa JA, Elisei R, Jarzab B, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin and paclitaxel in anaplastic thyroid cancer: final survival analysis for FACT trial. J Clin Oncol 2011;29(Suppl):abstract 5502
57. Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A-4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2036-41
58. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(Suppl):3550
59. Garon EB, Kabbinavar FF, Neidhart JA, et al. A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin, paclitaxel and bevacizumab in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 2011;29(Suppl):abstract 7559
60. Bevacizumab with or without fosbretabulin tromethamine in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01305213
61. Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17:25-31
62. Mita M, Spear MA, Yee LK, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 2010;16(23):5892-9
63. Lloyd GK, Nicholson B, Neuteboom STC, et al. NPI-2358: a new vascular/tubulin modifying agent greatly potentiates standard chemotherapy in xenograft models. EORTC-NCI-AACR Molecular Targets and Therapeutics Meeting; Boston, MA; 2003
64. Neuteboom STC, Medina E, Palladino MA, et al. NPI-2358, A novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV52 [abstract 141]. Eur J Cancer 2008;6(Suppl):40-0
65. Millward M, Mainwaring P, Mita A, et al. Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel. Invest New Drugs 2012;30:1065-73
66. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
67. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22158997
68. Mita AC, Heist RS, Aren O, et al. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC) [abstract 7592]. J Clin Oncol 2010;28(Suppl)):15s
69. Sessa C, Lorusso P, Tolcher AW, et al. A pharmacokinetic and DCE-MRI-dynamic phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Amer Assoc Cancer Res 2005;46
70. Chebil M, Soria J, Chami L, et al. Interest of DCE-US with quantification to demonstrate the VDA effect on vascularization in patients with advanced solid tumors treated with AVE8062. J Clin Oncol 2009;27(Suppl):e14522
71. A study of AVE8062 in advanced-stage soft tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00699517
72. AVE8062 in association with doublet chemotherapy cisplatin and docetaxel in advanced solid tumor. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00719524
73. Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18(10):1541-8
74. Ong M, del Conte G, Bahleda R, et al. A phase I study of ombrabulin combined with bevacizumab in patients with advanced solid tumors-preliminary results [abstract L6.5]. Anals Oncology 2012;23(Suppl):i15-25
75. Kurzrock R, Akerley W, Hong D, et al. Two Phase 1 studies of MPC-6827, a novel vascular disrupting agents (VDA), in patients with advanced solid tumors and CNS metastasis. J Clin Oncol 2007;25(20 Suppl):3604
76. Tsimberidou AM, Akerley W, Schabel MC, et al. Phase I Clinical Trial of MPC-6827 (Azixa), A Microtubule Destabilizing Agent, in Patients with Advanced Cancer. Mol Cancer Ther 2010;9:3410-19
77. Phase 2 study of Azixa (MPC-6827) for the treatment of glioblastoma after bevacizumab failure. Society for Neuro-Oncology Scientific Meeting; 2010
78. Zhu J-J, Recht LD, Colman H, et al. Phase II study using the response assessment in neuro-oncology (RANO) criteria to evaluate the efficacy of verubulin with radiation therapy and temozolomide in subjects newly diagnosed with glioblastoma multiforme: part a safety and tolerability results [abstract OT-08]. Neuro-Oncology 2011;13:iii85-91
79. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl): abstract LBA5002
80. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-68
81. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
82. Sato S, Itamochi H. Bevacizumab and ovarian cancer. Curr Opin Obstet Gynecol 2012;24(1):8-13
83. Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 2012;48:1126-32
84. Clemenson C, Jouannot E, Merino-Trigo A, et al. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 2012; [Epub ahead of print]
85. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20(2):227-30